Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan (Reyvow), as a treatment for acute migraine; it’s meant to be taken after the onset of migraine pain. That pain can be with or without aura—flashes of light, blind spots, and tingling sensations that sometimes accompany a migraine attack. According to data from two Phase 3 tests, the FDA said that the Lilly (NYSE: LLY) drug beat a placebo… Read more »
UNDERWRITERS AND PARTNERS
